Study of CAP1-6D in Patients With Locally Advanced or Surgically Resected Pancreatic Adenocarcinoma

NCT00203892 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

23

Enrollment

OTHER

Sponsor class

Conditions

Pancreatic Adenocarcinoma

Interventions

BIOLOGICAL: modified CEA peptide (10mcg)
BIOLOGICAL: modified CEA peptide (100mcg)
BIOLOGICAL: modified CEA peptide (1000mcg)

Sponsor

University of Chicago